Proteases and protease inhibitors in tumor progression

116Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Our understanding of the role of matrix degrading proteases in cancer has dramatically expanded over the last two decades. From correlative observations linking proteases to cancer progression, we have accumulated evidence supporting a causal role for proteases in various steps of tumor progression and have become increasingly aware of the complex interactions that exist among proteases. Specific natural inhibitors of these proteases have also been identified and their role as potent cytostatic agents in cancer has been suggested. In this article some of the concepts on the role of proteases in cancer are discussed and examples of cooperation between matrix metalloproteinases and the plasmin/plasminogen activators system are presented. The role of protease inhibitors such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and plasminogen activator inhibitor-2 (PAI-2) as inhibitors of tumor growth, invasion and metastasis is discussed.

Cite

CITATION STYLE

APA

DeClerck, Y. A., Imren, S., Montgomery, A. M. P., Mueller, B. M., Reisfeld, R. A., & Laug, W. E. (1997). Proteases and protease inhibitors in tumor progression. Advances in Experimental Medicine and Biology, 425, 89–97. https://doi.org/10.1007/978-1-4615-5391-5_9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free